Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with fatty liver disease confirmed through a tissue sample (biopsy)
Who may not be able to join:
- People with a history of significant alcohol use
- People who have viral hepatitis (such as hepatitis B or C)
- People who have autoimmune hepatitis (where the immune system attacks the liver)
- People who have certain inherited metabolic conditions affecting the liver, such as hemochromatosis (excess iron), Wilson's disease (excess copper), or alpha-1 antitrypsin deficiency
- People who are taking medications known to be harmful to the liver, such as amiodarone
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Giatgen Spinas, Prof. MD, University Hospital Zurich, Endocrinology and Diabetology
Phone: +41 (0)44 255 11 11
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Disease regression/progression
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.